On January 31, 2022 Patrys reported its Quarterly Activities Report and 4C Quarterly Cash Flow Report (Press release, Patrys, JAN 31, 2022, View Source [SID1234607498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Standout achievements for this Quarter have included:

PAT-DX3 manufacturing development program significantly ahead of schedule;
Non-clinical studies further define biological and pharmaceutical profile of PAT-DX3 deoxymab and potential use for expanded clinical applications;
Business development momentum;
Rodent, non-GLP toxicology studies confirm an acceptable safety and tolerability profile for PAT-DX1; and,
Balance sheet capacity with closing cash balance of $10.76M at 31 Dec 2021, with an additional $2M in short-term investments.